Literature DB >> 23149299

Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.

Orazio Nicolotti1, Marco Catto, Ilenia Giangreco, Maria Barletta, Francesco Leonetti, Angela Stefanachi, Leonardo Pisani, Saverio Cellamare, Paolo Tortorella, Fulvio Loiodice, Angelo Carotti.   

Abstract

Matrix metalloproteinases (MMPs) are attractive biological targets that play a key role in many physiopathological processes such as degradation of extracellular matrix proteins, release and cleavage of cell-surface receptors, tumour progression, homeostatic regulation and innate immunity. A series of 5-hydroxy, 5-substituted pyrimidine-2,4,6-triones were rationally designed, prepared and tested as inhibitors of gelatinases MMP-2 and MMP-9 and collagenase MMP-8. On one side, the presence of the 5-hydroxyl group, that represents an typical feature of this class of compounds, ensured an attractive pharmacokinetic profile while on the other suitably substituted biaryl molecular fragments, attached to position 5 through a ketomethylene linker, guaranteed favourable interaction in the deep region of the S(1)' enzymatic subsite. This rational design led to the discovery of highly potent MMP inhibitors. In particular, biphenyl derivatives bearing at the para position COCH(3) and OCF(3) substituents permitted to inhibit gelatinases MMP-2 and MMP-9, with IC(50) values as low as 30 nM and 21 nM, respectively, whereas the introduction at the same position of the bulkier SO(2)CH(3) group afforded a potent collagenase MMP-8 inhibitor with an IC(50) value equal to 66 nM. Molecular docking simulations allowed us to elucidate key interactions driving the binding of the top active compounds towards their preferred MMP target.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149299     DOI: 10.1016/j.ejmech.2012.09.036

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  4 in total

1.  Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management.

Authors:  Amany Belal; Mohamed A Elanany; Eman Y Santali; Ahmed A Al-Karmalawy; Moustafa O Aboelez; Ali H Amin; Magda H Abdellattif; Ahmed B M Mehany; Hazem Elkady
Journal:  Molecules       Date:  2022-06-02       Impact factor: 4.927

2.  Ligand-based pharmacophore modeling and molecular dynamic simulation approaches to identify putative MMP-9 inhibitors.

Authors:  Bharat Kumar Reddy Sanapalli; Vidyasrilekha Yele; Srikanth Jupudi; Veera Venkata Satyanarayana Reddy Karri
Journal:  RSC Adv       Date:  2021-08-06       Impact factor: 4.036

Review 3.  Regulation and involvement of matrix metalloproteinases in vascular diseases.

Authors:  Matthew Amin; Sathnur Pushpakumar; Nino Muradashvili; Sourav Kundu; Suresh C Tyagi; Utpal Sen
Journal:  Front Biosci (Landmark Ed)       Date:  2016-01-01

4.  Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.

Authors:  Francesca Carofiglio; Daniela Trisciuzzi; Nicola Gambacorta; Francesco Leonetti; Angela Stefanachi; Orazio Nicolotti
Journal:  Molecules       Date:  2020-09-14       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.